Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Mu-opioid receptor agonists
RWJ-394674
Другие языки:

    RWJ-394674

    Подписчиков: 0, рейтинг: 0
    RWJ-394674
    RWJ-394674 Structure.svg
    Legal status
    Legal status
    • In general: legal
    Identifiers
    • N,N-diethyl-4-((8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl)benzamide
    PubChem CID
    ChemSpider
    ChEMBL
    Chemical and physical data
    Formula C33H38N2O
    Molar mass 478.680 g·mol−1
    3D model (JSmol)
    • CCN(CC)C(=O)c1ccc(cc1)C(=C2C[C@H]3CC[C@@H](C2)N3CCc4ccccc4)c5ccccc5
    • InChI=1S/C33H38N2O/c1-3-34(4-2)33(36)28-17-15-27(16-18-28)32(26-13-9-6-10-14-26)29-23-30-19-20-31(24-29)35(30)22-21-25-11-7-5-8-12-25/h5-18,30-31H,3-4,19-24H2,1-2H3/b32-29-/t30-,31+/m1/s1
    • Key:ZJOPBPNTQRUJNM-BPVGFELESA-N
      (verify)

    RWJ-394674 is a drug that is used in scientific research. It is a potent, orally active analgesic drug that produces little respiratory depression. RWJ-394674 itself is a potent and selective agonist for δ-opioid receptors, with a Ki of 0.24 nM at δ and 72 nM at μ. However once inside the body, RWJ-394674 is dealkylated to its monodesethyl metabolite RWJ-413216, which is a potent agonist at the μ-opioid receptor and has less affinity for δ (Ki 0.26 nM at μ, 46.7 nM at δ). The effect of RWJ-394674 when administered in vivo thus produces potent agonist effects at both μ and δ receptors through the combined actions of the parent drug and its active metabolite, with the δ-agonist effects counteracting the respiratory depression from the μ-opioid effects, and the only prominent side-effect being sedation.


    Новое сообщение